绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02186 绿叶制药

圣诞节休市 12-24 12:08:29

2.160

+0.030

+1.41%

最高2.160	最低2.120	成交量1,070万
今开2.140	昨收2.130	日振幅1.88%
总市值81.25亿	流通市值81.25亿	总股本37.62亿
成交额2,292万	换手率0.28%	流通股本37.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"绿叶制药","latestPrice":2.16,"timestamp":1735013309015,"preClose":2.13,"halted":0,"volume":10702500,"delay":0,"floatShares":3761670643,"shares":3761670643,"eps":0.15192248,"marketStatus":"圣诞节休市","marketStatusCode":7,"change":0.03,"latestTime":"12-24 12:08:29","open":2.14,"high":2.16,"low":2.12,"amount":22919747,"amplitude":0.018779,"askPrice":2.16,"askSize":403000,"bidPrice":2.15,"bidSize":184000,"shortable":3,"etf":0,"ttmEps":0.21780816080901597,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735263000000},"adr":0,"adjPreClose":2.13,"dividendRate":0.029556,"openAndCloseTimeList":[[1735003800000,1735012800000]],"volumeRatio":0.7529086919974831,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186","defaultTab":"news","newsList":[{"id":"2493482241","title":"医药周报：抗抑郁新药进入收获期，关注吉贝尔、翰森制药、绿叶制药等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2493482241","media":"国广有话说","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493482241?lang=zh_cn&edition=full","pubTime":"2024-12-22 21:45","pubTimestamp":1734875116,"startTime":"0","endTime":"0","summary":"建议关注有布局抑郁症新药的企业如吉贝尔、绿叶制药、翰森制药等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222215043ab8b7e4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222215043ab8b7e4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02186","03692","BK1191","688566","BK1583","BK1515","BK1574","BK1589","09939","BK1606"],"gpt_icon":0},{"id":"2492519333","title":"【券商聚焦】中泰国际首予绿叶制药(02186)”买入”评级 指其估值显著低于行业平均","url":"https://stock-news.laohu8.com/highlight/detail?id=2492519333","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492519333?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:54","pubTimestamp":1734573269,"startTime":"0","endTime":"0","summary":"公司目前估值显著低于行业平均，该行认为有提升空间。按照12.0倍2025EPER定价，目标价2.90港元，首次覆盖，给予”买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949934","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"gpt_icon":0},{"id":"2492603501","title":"中泰国际：首予绿叶制药(02186)”买入”评级 目标价2.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492603501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492603501?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:17","pubTimestamp":1734571045,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中泰国际发布研究报告称，首次覆盖绿叶制药，给予”买入”评级，预计2023-26E收入CAGR为7.2%。按照12.0倍2025EPER定价，目标价2.9港元。肿瘤与心血管业务收入下半年起将逐步回暖公司肿瘤药包括用于卵巢癌、肺癌、乳腺癌等的力朴素、前列腺癌及乳腺癌药百拓维、小细胞肺癌药赞必佳等。欧开能广泛用于手术与炎症消肿，预计2024-26E销量将快速增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186"],"gpt_icon":0},{"id":"2492470164","title":"绿叶制药获执行主席刘殿波增持合共200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492470164","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492470164?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:23","pubTimestamp":1734567780,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　绿叶制药（02186）发布公告，获公司的执行董事兼执行主席刘殿波通知，彼于2024年12月18日透过其受控法团绿叶制药投资有限公司于市场内购入合共公司的200万股普通股，平均购入价为每股股份约2.2299港元。进行购买后及于本公告日期，刘先生于12.61亿股股份中拥有权益，占公司已发行股本总额约33.53%。\n　　如刘先生所告知，彼对公司的增长、发展及未来前景充满信心，并可能于适当时在适用法律及法规的规限下进一步增加彼于股份的权益。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-19/doc-inczxzya0292510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1606","BK1583","BK1191","02186"],"gpt_icon":0},{"id":"2492353011","title":"绿叶制药(02186.HK)控股股东均价2.23元增持200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492353011","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492353011?lang=zh_cn&edition=full","pubTime":"2024-12-19 00:29","pubTimestamp":1734539340,"startTime":"0","endTime":"0","summary":"绿叶制药(02186.HK) 公布，12月18日，主席刘殿波透过其受控法团绿叶制药投资于市场内购入公司200万股，每股平均价2.2299元。完成后，刘氏持有公司总股本33.53%。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-18 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405060/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1191","02186","BK1606"],"gpt_icon":0},{"id":"2492297183","title":"绿叶制药控股股东增持200万股 持股比例增至总股本的33.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492297183","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492297183?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:50","pubTimestamp":1734526240,"startTime":"0","endTime":"0","summary":"财中社12月18日电绿叶制药（02186）发布自愿性公告，控股股东于2024年12月18日增持本公司股权。执行董事兼执行主席刘殿波通过其受控法团绿叶制药投资有限公司，在市场内购入200万股普通股，平均购入价为每股约2.2299港元。购入后，刘殿波持有本公司12.61亿股股份，权益占本公司已发行股本总额约33.53%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272274197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02186","BK1606","BK1191","BK1583"],"gpt_icon":0},{"id":"2492890063","title":"绿叶制药(02186)获执行主席刘殿波增持合共200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492890063","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492890063?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:34","pubTimestamp":1734525241,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药(02186)发布公告，获公司的执行董事兼执行主席刘殿波通知，彼于2024年12月18日透过其受控法团绿叶制药投资有限公司于市场内购入合共公司的200万股普通股，平均购入价为每股股份约2.2299港元。进行购买后及于本公告日期，刘先生于12.61亿股股份中拥有权益，占公司已发行股本总额约33.53%。如刘先生所告知，彼对公司的增长、发展及未来前景充满信心，并可能于适当时在适用法律及法规的规限下进一步增加彼于股份的权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186","BK1606","BK1191","BK1583"],"gpt_icon":0},{"id":"2492497521","title":"绿叶制药(02186)出现大手卖出90.15万股，成交价$2.21，涉资199.232万","url":"https://stock-news.laohu8.com/highlight/detail?id=2492497521","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492497521?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:29","pubTimestamp":1734506940,"startTime":"0","endTime":"0","summary":"[大手成交]绿叶制药(02186)在下午03:29出现大手卖出，成交量为90.15万，成交价为港币$2.21，涉资199.232万。至目前为止，股价跌1.778%，今日最高价为$2.26，而最低价为$2.2，总成交量为2.264千万股，总成交金额港币$5.026千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2412184863/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1191","BK1606","02186"],"gpt_icon":0},{"id":"2492877089","title":"绿叶制药12月17日主力资金流出226万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492877089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492877089?lang=zh_cn&edition=full","pubTime":"2024-12-17 16:16","pubTimestamp":1734423402,"startTime":"0","endTime":"0","summary":"12月17日, 绿叶制药股价跌1.32%，报收2.25元，成交金额4916万元，换手率0.58%，振幅3.51%，量比0.79。绿叶制药今日主力资金净流出226万元，连续3日净流出，上一交易日主力净流出596万元，今日环比减少62.08%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为47.62%，平均跌幅为2.39%。该股近5个交易日下跌7.02%，主力资金累计净流出1711万元；近20日主力资金累计净流出5438万元，其中净流出天数为14日。该股主力净额占比0.03%，港股市场排名2526/2654。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161736ab7e940b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161736ab7e940b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02186","BK1583","BK1606"],"gpt_icon":0},{"id":"2491684194","title":"绿叶制药(02186.HK)完成发行5,000万美元可转换债券 利率5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491684194","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491684194?lang=zh_cn&edition=full","pubTime":"2024-12-16 10:19","pubTimestamp":1734315540,"startTime":"0","endTime":"0","summary":"绿叶制药(02186.HK) 公布，发行5,000万美元5.85%利率2025年到期可转换债券之所有先决条件已获达成，且发行相关债券已顺利完成。预期相关债券于新交所上市将于今日(16日)生效。绿叶制药表示，是次发行可以改善集团的资金流动性以及替换部分短期贷款，是次发行债券所得款项净额将减少集团的资金成本并改善债务到期情况。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-13 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404243/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["ZFmain","02186","ZBmain","BK1606","TNmain","ZTmain","BK1191","BK1583","UBmain","ZNmain"],"gpt_icon":0},{"id":"2491055443","title":"绿叶制药完成发行5000万美元的可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2491055443","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491055443?lang=zh_cn&edition=full","pubTime":"2024-12-14 16:56","pubTimestamp":1734166560,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　绿叶制药（02186）公布，就公司发行5000万美元5.85%利率2025年到期可转换债券（B期债券），B期认购协议所载发行B期债券的所有先决条件已获达成，且发行B期债券已顺利完成。预期B期债券于新交所上市将于2024年12月16日生效。\n　　董事会认为通过B期债券发行可以改善集团的资金流动性以及替换集团部分短期贷款。董事会认为，是次发行B期债券所得款项净额将减少集团的资金成本并改善集团的债务到期情况。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-14/doc-inczmpnp1635160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","02186","BK1583","BK1606"],"gpt_icon":0},{"id":"2491372887","title":"绿叶制药完成发行5000万美元2025年到期可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2491372887","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491372887?lang=zh_cn&edition=full","pubTime":"2024-12-13 23:07","pubTimestamp":1734102422,"startTime":"0","endTime":"0","summary":"格隆汇12月13日丨绿叶制药(02186.HK)公告，内容有关(其中包括)公司发行5000万美元5.85%利率2025年到期可转换债券。B期认购协议所载发行B期债券所有先决条件已获达成，且发行B期债券已顺利完成。预期B期债券于新交所上市将于2024年12月16日生效。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213231120ab75a03e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213231120ab75a03e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02186","BK1606","BK1191","BK1583"],"gpt_icon":0},{"id":"2491753293","title":"绿叶制药(02186)完成发行5000万美元的可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2491753293","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491753293?lang=zh_cn&edition=full","pubTime":"2024-12-13 22:32","pubTimestamp":1734100345,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药(02186)公布，就公司发行5000万美元5.85%利率2025年到期可转换债券(B期债券)，B期认购协议所载发行B期债券的所有先决条件已获达成，且发行B期债券已顺利完成。预期B期债券于新交所上市将于2024年12月16日生效。董事会认为通过B期债券发行可以改善集团的资金流动性以及替换集团部分短期贷款。董事会认为，是次发行B期债券所得款项净额将减少集团的资金成本并改善集团的债务到期情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186","BK1583","BK1606","BK1191"],"gpt_icon":0},{"id":"2491393523","title":"绿叶制药(02186)出现大手卖出81.75万股，成交价$2.42，涉资197.835万","url":"https://stock-news.laohu8.com/highlight/detail?id=2491393523","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491393523?lang=zh_cn&edition=full","pubTime":"2024-12-13 09:30","pubTimestamp":1734053400,"startTime":"0","endTime":"0","summary":"[大手成交]绿叶制药(02186)在上午09:30出现大手卖出，成交量为81.75万，成交价为港币$2.42，涉资197.835万。至目前为止，股价跌1.22%，今日最高价为$2.46，而最低价为$2.42，总成交量为130.05万股，总成交金额港币$315.97万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV24121324/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02186","BK1606","BK1583"],"gpt_icon":0},{"id":"2490880612","title":"绿叶制药12月11日主力资金流出656万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2490880612","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490880612?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:15","pubTimestamp":1733904935,"startTime":"0","endTime":"0","summary":"12月11日, 绿叶制药股价跌0.83%，报收2.40元，成交金额6599万元，换手率0.73%，振幅2.48%，量比1.00。绿叶制药今日主力资金净流出656万元，连续7日净流出，上一交易日主力净流出597万元，今日环比增加9.88%。该股近5个交易日下跌4.00%，主力资金累计净流出3331万元；近20日主力资金累计净流出5199万元，其中净流出天数为14日。该股主力净额占比0.07%，港股市场排名2607/2650。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161546a1e59cc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161546a1e59cc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02186","BK1606","BK1191","BK1583"],"gpt_icon":0},{"id":"2489283005","title":"打破小细胞肺癌二线治疗少药瓶颈，绿叶制药赞必佳获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2489283005","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489283005?lang=zh_cn&edition=full","pubTime":"2024-12-06 19:35","pubTimestamp":1733484955,"startTime":"0","endTime":"0","summary":"大多数患者在初始治疗后出现耐药及复发，接受进一步的化疗后中位总生存期仅为4-5个月。近日，绿叶制药创新药注射用芦比替定作为纳入优先审评审批程序的品种，获得国家药品监督管理局的上市批准，适用于治疗含铂化疗中或化疗后疾病进展的转移性小细胞肺癌成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/246402","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","BK1606","BK1583","02186"],"gpt_icon":0},{"id":"2488905550","title":"智通港股早知道 | 四大行业协会呼吁谨慎采购美国芯片 商务部加强相关两用物项对美出口","url":"https://stock-news.laohu8.com/highlight/detail?id=2488905550","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488905550?lang=zh_cn&edition=full","pubTime":"2024-12-04 07:38","pubTimestamp":1733269080,"startTime":"0","endTime":"0","summary":"四大行业协会齐发声：谨慎采购美国芯片中国互联网协会、中国汽车工业协会、中国半导体行业协会、中国通信企业协会均发布声明，呼吁国内企业审慎选择采购美国芯片。任何国家和地区的组织和个人，违反上述规定，将原产于中华人民共和国的相关两用物项转移或提供给美国的组织和个人，将依法追究法律责任。公司现已通过金誊矿业持有La Arena项目100%权益。此前，该联合疗法获中国国家药品监督管理局纳入优先评审及突破性治疗品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e109f46a42f6e105cba86a08da6bd2f3","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1191","LU1969619763.USD","BK1240","HSTECH","BK1161","BK1588","00013","BK1587","BK1606","LU2488822045.USD","02186","159813","BK1583","YANG","HSCEI","00123","BK1555","LU2328871848.SGD","01801"],"gpt_icon":1},{"id":"2488993138","title":"【港股通】绿叶制药(02186)：赞必佳在中国大陆获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2488993138","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488993138?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:58","pubTimestamp":1733216335,"startTime":"0","endTime":"0","summary":"金吾财讯 | 绿叶制药(02186)公布，集团的创新药赞必佳（注射用芦比替定）作为被纳入优先审评审批程序的品种，已获得中国国家药品监督管理局的上市批准，适用于治疗含铂化疗中或化疗后疾病进展的转移性小细胞肺癌(SCLC)成人患者。公司称，赞必佳是一种选择性的致癌基因转录抑制剂，在抑制肿瘤基因转录、导致肿瘤细胞雕亡的同时，可调节肿瘤微环境，进一步发挥抗肿瘤作用。该产品于2020年获得美国食品药品监督管理局(FDA)的附条件批准。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MTA1YTkyMTYzODE2MDY0MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTA1YTkyMTYzODE2MDY0MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948885","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","YANG","BK1191","02186","BK1606","HSCEI","HSTECH"],"gpt_icon":0},{"id":"2488893998","title":"绿叶制药(02186)：赞必佳®(注射用芦比替定)在中国大陆获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2488893998","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488893998?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:35","pubTimestamp":1733214945,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，集团的创新药赞必佳作为被纳入优先审评审批程序的品种，已获得中国国家药品监督管理局的上市批准，适用于治疗含铂化疗中或化疗后疾病进展的转移性小细胞肺癌成人患者。赞必佳获得国家药品监督管理局的上市批准，主要基于两项临床研究结果。截至目前，赞必佳共在全球17个国家或地区获得上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02186","BK1583","BK1606"],"gpt_icon":0},{"id":"2488989929","title":"绿叶制药(02186.HK)创新药赞必佳获得国家药监局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2488989929","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488989929?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:33","pubTimestamp":1733214780,"startTime":"0","endTime":"0","summary":"绿叶制药(02186.HK) 公布，其创新药赞必佳(注射用芦比替定)作为被纳入优先审评审批程序的品种，已获得中国国家药品监督管理局的上市批准，适用于治疗含铂化疗中或化疗后疾病进展的转移性小细胞肺癌(SCLC)成人患者。截至目前，赞必佳共在全球17个国家或地区获得上市批准。集团获权在内地、香港、澳门地区开发和商业化该产品，并已成功推动其在上述三地获批上市。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-03 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401452/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02186","159992","06978","BK1583","BK1606","BK1161","BK1191","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":-0.1529},{"period":"3month","weight":-0.3055},{"period":"6month","weight":-0.2059},{"period":"1year","weight":-0.3829},{"period":"ytd","weight":-0.4209}],"compareEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":0.0452},{"period":"3month","weight":0.0507},{"period":"6month","weight":0.1344},{"period":"1year","weight":0.23},{"period":"ytd","weight":0.179}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"绿叶制药集团有限公司是一家主要从事开发、生产、推广及销售药品的投资控股公司。公司及其子公司通过四大分部运营：肿瘤药物分部、心血管系统药物分部、消化与代谢药物分部和其他分部。该公司的主要产品包括用于癌症的化学治疗的备紫杉醇类制剂，用于实体肿瘤的放射治疗的注射用化合物，用于治疗高脂血症治疗的中药，用于治疗二型糖尿病的阿卡波糖胶囊，用于治疗老年痴呆症的卡巴拉汀透皮贴片等。产品以力扑素，希美纳，血脂康，麦通纳，贝希等品牌销售。该公司通过其子公司还从事提供合约研究及程序开发业务。该公司主要在中国内地运营业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.026366},{"month":2,"riseRate":0.3,"avgChangeRate":0.013725},{"month":3,"riseRate":0.4,"avgChangeRate":-0.015714},{"month":4,"riseRate":0.5,"avgChangeRate":-0.00409},{"month":5,"riseRate":0.3,"avgChangeRate":-0.034213},{"month":6,"riseRate":0.3,"avgChangeRate":-0.003238},{"month":7,"riseRate":0.6,"avgChangeRate":-0.000283},{"month":8,"riseRate":0.181818,"avgChangeRate":-0.034124},{"month":9,"riseRate":0.636364,"avgChangeRate":0.054933},{"month":10,"riseRate":0.545455,"avgChangeRate":0.000249},{"month":11,"riseRate":0.545455,"avgChangeRate":0.028629},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.004164}],"exchange":"SEHK","name":"绿叶制药","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿叶制药,02186,绿叶制药股票,绿叶制药股票老虎,绿叶制药股票老虎国际,绿叶制药行情,绿叶制药股票行情,绿叶制药股价,绿叶制药股市,绿叶制药股票价格,绿叶制药股票交易,绿叶制药股票购买,绿叶制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}